Search results for "Histocompatibility"

showing 10 items of 473 documents

T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

2021

Abstract Purpose: Gliomas are intrinsic brain tumors with a high degree of constitutive and acquired resistance to standard therapeutic modalities such as radiotherapy and alkylating chemotherapy. Glioma subtypes are recognized by characteristic mutations. Some of these characteristic mutations have shown to generate immunogenic neoepitopes suitable for targeted immunotherapy. Experimental Design: Using peptide-based ELISpot assays, we screened for potential recurrent glioma neoepitopes in MHC-humanized mice. Following vaccination, droplet-based single-cell T-cell receptor (TCR) sequencing from established T-cell lines was applied for neoepitope-specific TCR discovery. Efficacy of intravent…

Cancer ResearchT-LymphocytesT cellCellchemical and pharmacologic phenomenaRecurrent GliomaMajor histocompatibility complexImmunotherapy AdoptiveMiceGliomamedicineAnimalsMHC class IIReceptors Chimeric AntigenbiologyELISPOTT-cell receptorGliomamedicine.diseaseDisease Models Animalmedicine.anatomical_structureOncologybiology.proteinCancer researchImmunotherapyNeoplasm Recurrence LocalClinical Cancer Research
researchProduct

Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1.

1994

Cytolytic T lymphocyte (CTL) clones have previously been derived from peripheral blood of melanoma patient SK29(AV). They lyse autologous melanoma cells but not autologous Epstein-Barr virus (EBV)-transformed B lymphocytes. Immunoselection experiments indicate that these CTL clones recognize 4 different antigens (Aa, Ab, B, C) in association with a single HLA restriction element, HLA-A2.1. While the expression of antigens B and C appears to be confined to SK29-melanoma cells, antigens Aa and Ab are shared by a high proportion of allogeneic HLA-A2-positive melanoma lines. HLA-A2.1 and total HLA class I molecules have now been purified from SK29-melanoma cells using affinity chromatography an…

Cancer Researchmedicine.drug_classAntigen processingHistocompatibility Antigens Class IHuman leukocyte antigenT lymphocyteBiologyMonoclonal antibodyVirologyMolecular biologyNeoplasm ProteinsCTL*OncologyAffinity chromatographyAntigenAntigens NeoplasmmedicineTumor Cells CulturedHumansPan-T antigensMelanomaChromatography High Pressure LiquidT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor …

2003

Silencing of a specific mRNA using double stranded RNA oligonucleotides represents one of the newest technologies for suppressing a specific gene product. Small interfering RNA (siRNA) are 21 nucleotides long, double stranded RNA fragments that are identical in sequence to the target mRNA. We designed 3 such siRNA against the Her2/neu (HER2) gene. The HER2 gene is known to play an important role in the oncogenesis of several types of cancers, such as breast, ovarian, colon and gastric cancers. Introduction of the siRNA into HER2 positive tumor lines in vitro greatly reduced the cell surface expression of the HER2 protein. Concurrently, a range of effects on cell physiology, such as growth i…

Cancer Researchmedicine.medical_specialtySmall interfering RNAApoptosisBreast NeoplasmsAntibodies Monoclonal HumanizedTransfectionHER2/neuGene productRNA interferenceInternal medicineCell Line TumormedicineGene silencingHumansGene SilencingRNA Small Interferingskin and connective tissue diseasesneoplasmsOvarian NeoplasmsMessenger RNAbiologyHistocompatibility Antigens Class IRNAAntibodies MonoclonalTransfectionGenes erbB-2TrastuzumabUp-RegulationEndocrinologyOncologyCancer researchbiology.proteinFemaleInternational journal of cancer
researchProduct

Dendritic cell-tumor cell hybrids and immunotherapy: what's next?

2011

Dendritic cells (DC) are professional antigen-presenting cells currently being used as a cellular adjuvant in cancer immunotherapy strategies. Unfortunately, DC-based vaccines have not demonstrated spectacular clinical results. DC loading with tumor antigens and DC differentiation and activation still require optimization. An alternative technique for providing antigens to DC consists of the direct fusion of dendritic cells with tumor cells. These resulting hybrid cells may express both major histocompatibility complex (MHC) class I and II molecules associated with tumor antigens and the appropriate co-stimulatory molecules required for T-cell activation. Initially tested in animal models, …

Cancer Researchmedicine.medical_treatmentImmunologyAntigen-Presenting CellsHybrid CellsMajor histocompatibility complexAntigenCancer immunotherapyAntigens NeoplasmNeoplasmsmedicineImmunology and AllergyAnimalsHumansGenetics (clinical)TransplantationCell fusionMembrane GlycoproteinsbiologyHistocompatibility Antigens Class IHistocompatibility Antigens Class IICell BiologyDendritic cellImmunotherapyDendritic CellsCell biologyMembrane glycoproteinsDisease Models AnimalOncologybiology.proteinImmunotherapyAdjuvantCytotherapy
researchProduct

Heat Shock Protein Vaccines Against Cancer

1993

Vaccination of mice with heat shock proteins (HSPs) derived from a tumor makes the mice resistant to the tumor from which the HSP was obtained. This phenomenon has been demonstrated with three HSPs--gp96, hsp90, and hsp70. Vaccination with HSPs also elicits antigen-specific cytotoxic T lymphocytes (CTLs). The specific immunogenicity of HSPs derives apparently, not from the HSPs per se, but from the peptides bound to them. These observations provide the basis for a new generation of vaccines against cancer. The HSP-based cancer vaccines circumvent two of the most intractable hurdles to cancer immunotherapy. One of them is the possibility that human cancers, like cancers of experimental anima…

Cancer Researchmedicine.medical_treatmentImmunologychemical and pharmacologic phenomenaBiologyInfectionsEpitopeMiceImmune systemAntigenCancer immunotherapyHeat shock proteinmedicineAnimalsImmunology and AllergyCytotoxic T cellHeat-Shock ProteinsPharmacologyMice Inbred BALB CMice Inbred C3HHistocompatibility Antigens Class IVaccinationCancerhemic and immune systemsImmunotherapymedicine.diseaseImmunologySarcoma ExperimentalT-Lymphocytes CytotoxicJournal of Immunotherapy
researchProduct

Analysis of TCR Vbeta repertoire and cytokine gene expression in patients with idiopathic dilated cardiomyopathy

2001

Although the etiopathogenesis of idiopathic dilated cardiomyopathy (IDC) is still unclear, it is widely accepted that a complex interplay between viral infections and immune mechanisms is the basis of disease genesis. Previously, we showed that heart-infiltrating T cells of patients suffering from acute, fulminant Coxsackie virus B3+-IDC shared a preferential usage of three variable gene segments of the T cell receptor beta chain-(TCR-Vbeta) encoding families Vbeta3, 7 and 13.1. This indicated the possible presence of a superantigen-driven immune response. Here, we further investigated the IDC immunological scenario by analysing different phenotypes of heart-infiltrating cells: TCR repertoi…

Cardiomyopathy DilatedInterleukin 2MyocarditisCD8 AntigensReceptors Antigen T-Cell alpha-betaT cellImmunologyCardiomyopathyGene Expressionchemical and pharmacologic phenomenaPicornaviridaeBiologyHLA-DQ alpha-ChainsImmunoenzyme TechniquesInterferon-gammaImmune systemAntigenHLA-DQ AntigensIdiopathic dilated cardiomyopathymedicineHLA-DQ beta-ChainsHumansImmunology and AllergyRNA MessengerAntigens ViralInterleukin-6Reverse Transcriptase Polymerase Chain ReactionHistocompatibility TestingMyocardiumIDC cytokines immune mechanismsmedicine.diseaseEnterovirus B HumanMyocarditismedicine.anatomical_structureCD4 AntigensImmunologyLeukocytes MononuclearCytokinesInterleukin-2Interleukin-4CD8Interleukin-1medicine.drug
researchProduct

Cathepsin B in Antigen-Presenting Cells Controls Mediators of the Th1 Immune Response during Leishmania major Infection

2014

Resistance and susceptibility to Leishmania major infection in the murine model is determined by the capacity of the host to mount either a protective Th1 response or a Th2 response associated with disease progression. Previous reports involving the use of cysteine cathepsin inhibitors indicated that cathepsins B (Ctsb) and L (Ctsl) play important roles in Th1/Th2 polarization during L. major infection in both susceptible and resistant mouse strains. Although it was hypothesized that these effects are a consequence of differential patterns of antigen processing, the mechanisms underlying these differences were not further investigated. Given the pivotal roles that dendritic cells and macrop…

Cathepsin Lmedicine.medical_treatmentCathepsin BCathepsin BWhite Blood CellsMiceAnimal CellsMedicine and Health SciencesLeishmaniasisLeishmania majorProtozoansAntigen PresentationMice Inbred BALB CT CellsAntigen processinglcsh:Public aspects of medicineInterleukin-12Up-RegulationInfectious DiseasesCytokineInterleukin 12FemaleCellular TypesResearch ArticleNeglected Tropical Diseaseslcsh:Arctic medicine. Tropical medicinelcsh:RC955-962Immune CellsImmunologyAntigen presentationAntigen-Presenting CellsMice TransgenicBiologyMajor histocompatibility complexmedicineAnimalsAntigen-presenting cellMHC class IIBlood CellsMacrophagesOrganismsPublic Health Environmental and Occupational HealthBiology and Life Scienceslcsh:RA1-1270Cell BiologyDendritic CellsTh1 CellsTropical DiseasesMolecular biologyParasitic ProtozoansDisease Models AnimalImmunologybiology.proteinPLoS Neglected Tropical Diseases
researchProduct

Induction of secondary cytotoxic T-lymphocytes in vitro does not require cell proliferation.

1976

SummaryUsing a mouse in vitro allograft model, evidence has been obtained that, in contrast to the accepted view, the generation of cytotoxic effector function in T-lymphocytes does not necessarily require cell division.

Cell divisionCell growthEffectorT-LymphocytesMice Inbred StrainsBiologymedicine.diseaseCytotoxicity Tests ImmunologicGeneral Biochemistry Genetics and Molecular BiologyIn vitroMitomycinsTissue cultureMiceHistocompatibility AntigensImmunologyCancer researchmedicineNeoplasmCytotoxic T cellAnimalsImmunologic MemoryFunction (biology)Cell DivisionProceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
researchProduct

Rapid and Sensitive Identification of Major Histocompatibility Complex Class I-associated Tumor Peptides by Nano-LC MALDI MS/MS

2005

Identification of major histocompatibility complex (MHC)-associated peptides recognized by T-lymphocytes is a crucial prerequisite for the detection and manipulation of specific immune responses in cancer, viral infections, and autoimmune diseases. Unfortunately immunogenic peptides are less abundant species present in highly complex mixtures of MHC-extracted material. Most peptide identification strategies use microcapillary LC coupled to nano-ESI MS/MS in a challenging on-line approach. Alternatively MALDI PSD analysis has been applied for this purpose. We report here on the first off-line combination of nanoscale (nano) LC and MALDI TOF/TOF MS/MS for the identification of naturally proce…

CellsCellPeptideHuman leukocyte antigenMajor histocompatibility complexSensitivity and SpecificityBiochemistryEpitopeAnalytical ChemistryMajor Histocompatibility ComplexImmune systemCell Line TumormedicineHumansAmino Acid SequenceCarcinoma Renal CellMolecular Biologychemistry.chemical_classificationbiologyHistocompatibility Antigens Class IFlow CytometryMolecular biologyKidney NeoplasmsPeptide FragmentsNeoplasm Proteinsmedicine.anatomical_structurechemistrySpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationbiology.proteinTime-of-flight mass spectrometryAntibodyMolecular & Cellular Proteomics
researchProduct

Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo

2012

Increasing evidence suggests that antibodies can have stimulatory effects on T-cell immunity. However, the contribution of circulating antigen-specific antibodies on MHC class I cross-priming in vivo has not been conclusively established. Here, we defined the role of circulating antibodies in cross-presentation of antigen to CD8(+) T cells. Mice with hapten-specific circulating antibodies, but naϊve for the T-cell antigen, were infused with haptenated antigen and CD8(+) T-cell induction was measured. Mice with circulating hapten-specific antibodies showed significantly enhanced cross-presentation of the injected antigen compared with mice that lacked these antibodies. The enhanced cross-pre…

Cellular immunityOvalbuminImmunologyMice Transgenicchemical and pharmacologic phenomenaAntigen-Antibody ComplexCD8-Positive T-LymphocytesBiologyDendritic cellsAntibodiesMiceCross-PrimingImmune systemAntigenAntigens NeoplasmMHC class ITcellsAnimalsImmunology and AllergyImmunity CellularB cellsCross-presentationHistocompatibility Antigens Class ICross-presentationSerum Albumin BovineFlow CytometryCD11c AntigenMice Inbred C57BLMacrophage-1 antigenHumoral immunityImmunologybiology.proteinAntibodyHaptensEuropean Journal of Immunology
researchProduct